Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorsBrandon Ason, Duncan Brown, Walter R. Strapps
Estimating the term…
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of PHD2 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against PHD2 gene expression.
A double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of prolyl hydroxylase domain 2 (PHD2) comprising a sense strand and an antisense strand, wherein the antisense strand comprises a nucleotide sequence of at least 15 contiguous nucleotides having sequence complementarity to 5′-GUGACAUGUAUAUAUUAUC-3′ (SEQ ID NO:
Dependencies are inferred from the claim text.